{"url_path":"/sec/kytx/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-227920-index.html","accession_number":"0001193125-26-227920","cik":"0001994702","ticker":"KYTX","issuer_name":"Kyverna Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-227920-index.html","primary_entity_key":"0001994702","primary_entity_name":"Kyverna Therapeutics, Inc."},"word_count":105,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n(d) Exhibits.\n\n \n\n \n\n \n\n \n\nNumber\n\n \n\n  Description\n\n \n\n \n\n \n\n10.1\n\n \n\n[Employment Offer Letter, dated May 8, 2026, between Kyverna Therapeutics, Inc. and Gregory Martini.](kytx-ex10_1.htm)\n\n10.2\n\n \n\n[Letter Agreement, dated May 14, 2026, between Kyverna Therapeutics, Inc. and Marc Grasso.](kytx-ex10_2.htm)\n\n99.1\n\n \n\n[Press Release, dated May 18, 2026.](kytx-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nKyverna Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 18, 2026\n\nBy:\n\n/s/ Warner Biddle\n\n \n\n \n\n \n\nWarner Biddle\nChief Executive Officer"}